Newlink Genetics Cor (NLNK) 9.81 $NLNK
NewLink Genetics to Participate in Baird Healthcare Conference
GlobeNewswire - Thu Sep 01, 6:00AM CDT
NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company focused on bringing novel immuno-oncology therapies to patients with cancer, today announced that it will participate in the Baird Healthcare Conference in New York.
NLNK: 9.81 (-0.50)
NewLink Genetics Reports Second Quarter 2016 Financial Results
GlobeNewswire - Fri Jul 29, 7:00AM CDT
- Management to Host Conference Call Today at 8:30 a.m. ET
NLNK: 9.81 (-0.50)
IMPORTANT SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against NewLink Genetics Corporation and Reminds Investors with Losses to Contact the Firm
BusinessWire - Thu Jun 23, 7:17PM CDT
Lundin Law PC announces a class action lawsuit has been filed against NewLink Genetics Corporation ("NewLink" or the "Company"
(Nasdaq: NLNK) concerning possible violations of federal securities laws between September 17, 2013 and May 9, 2016. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the July 11, 2016 lead plaintiff motion deadline.
NLNK: 9.81 (-0.50)
The Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of NewLink Genetics Corporation Investors and Encourages Investors to Contact the Firm
BusinessWire - Thu Jun 23, 1:21PM CDT
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased NewLink Genetics Corporation ("NewLink" or the "Company" (NASDAQ: NLNK) securities between September 17, 2013 and May 9, 2016, inclusive (the "Class Period". NewLink investors have until July 11, 2016 to file a lead plaintiff motion.
NLNK: 9.81 (-0.50)
DEADLINE ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against NewLink Genetics Corporation and Reminds Investors with Losses to Contact the Firm
BusinessWire - Thu Jun 23, 4:30AM CDT
Lundin Law PC announces a class action lawsuit has been filed against NewLink Genetics Corporation ("NewLink" or the "Company" (Nasdaq: NLNK) concerning possible violations of federal securities laws between September 17, 2013 and May 9, 2016. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the July 11, 2016 lead plaintiff motion deadline.
NLNK: 9.81 (-0.50)
NEWLINK SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against NewLink Genetics Corporation - NLNK
PR Newswire - Fri Jun 10, 9:07PM CDT
Kahn Swick & Foti, LLC ("KSF" and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 11, 2016 to file lead plaintiff applications in a securities class action lawsuit against NewLink Genetics Corporation (NasdaqGM: NLNK), if they purchased the Company's securities between September 17, 2013 and May 9, 2016, inclusive (the "Class Period". This action is pending in the United States District Court for the Southern District of New York.
NLNK: 9.81 (-0.50)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in NewLink Genetics Corporation of Class Action Lawsuit and Upcoming Deadline - NLNK
ACCESSWIRE - Fri Jun 10, 5:21PM CDT
NEW YORK, NY / ACCESSWIRE / June 10, 2016 / Pomerantz LLP announces that a class action lawsuit has been filed against NewLink Genetics Corporation ("NewLink" or the "Company" (NASDAQ: NLNK) and certain of its officers. The class action, filed in United States District Court, Southern District of New York, and docketed under 16-cv-03545, is on behalf of a class consisting of all persons or entities who purchased NewLink securities between September 17, 2013 and May 9, 2016 inclusive (the "Class Period". This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act".
NLNK: 9.81 (-0.50)
INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Class Action Involving NewLink Genetics Corporation and a Lead Plaintiff Deadline of July 11, 2016 - NLNK
GlobeNewswire - Fri Jun 10, 9:51AM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased NewLink Genetics Corporation (NASDAQ:NLNK) securities between September 17, 2013 and May 9, 2016.
NLNK: 9.81 (-0.50)
How These Biotech's Stocks are Performing? - Clovis Oncology, Illumina, NewLink Genetics and Zafgen
PR Newswire - Thu Jun 09, 7:00AM CDT
Some of the biggest opportunities in the equities market are found in tumultuous industries such as Biotechnology. The segment continues to present a number of remarkable trades as well as potentially good investment that are waiting to be discovered. This morning ActiveWallSt.com features these four biotech stocks in its technical alerts service: Clovis Oncology Inc. (NASDAQ: CLVS), Illumina Inc. (NASDAQ: ILMN), NewLink Genetics Corp. (NASDAQ: NLNK), and Zafgen Inc. (NASDAQ: ZFGN). Learn more about these stocks and receive your complimentary trade alerts at:
ZFGN: 2.94 (-0.10), CLVS: 23.38 (-0.21), NLNK: 9.81 (-0.50), ILMN: 167.90 (-0.66)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in NewLink Genetics Corporation to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit - NLNK
GlobeNewswire - Wed Jun 08, 2:22PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of NewLink Genetics Corporation (Nasdaq:NLNK) ("NewLink" or the "Company" securities during the period between September 17, 2013 and May 9, 2016, inclusive (the "Class Period". Investors with losses in excess of $100,000 who wish to become proactively involved in the litigation have until July 11, 2016 to seek appointment as lead plaintiff.
NLNK: 9.81 (-0.50)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of NewLink Genetics Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 11, 2016 - NLNK
GlobeNewswire - Mon Jun 06, 2:18PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
NLNK: 9.81 (-0.50)
Law Offices of Marc S. Henzel Announces Investigation of Companies for Violations of the Federal Securities Laws
PR Newswire - Mon Jun 06, 8:11AM CDT
The Law Offices of Marc S. Henzel (www.henzellaw.com), a firm focusing on shareholder litigation, gives notice to shareholders of investigation into the following securities for violations of the Federal Securities Laws:
TNGO: 9.65 (+0.13), ENDP: 19.92 (-0.31), GGB: 2.88 (+0.18), HCP: 39.06 (+0.26), UNIS: 2.79 (+0.01), NLNK: 9.81 (-0.50), ABIL: 4.52 (+0.03)
NewLink Genetics Presents Clinical Data for IDO Pathway Inhibitor Indoximod Combinations at American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire - Mon Jun 06, 6:00AM CDT
NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company focused on bringing novel immuno-oncology medicines to patients, yesterday presented data from two studies on two posters highlighting the combination therapeutic potential of indoximod, an indoleamine-(2,3)-dioxygenase (IDO) pathway inhibitor, at the 2016 American Society of Clinical Oncology Annual Meeting in Chicago.
NLNK: 9.81 (-0.50)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against NewLink Genetics Corporation (NLNK) and Lead Plaintiff Deadline: July 11, 2016
ACCESSWIRE - Fri Jun 03, 9:51AM CDT
NEW YORK, NY / ACCESSWIRE / June 3, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed on behalf of those who purchased shares of NewLink Genetics Corporation ("NewLink" or the "Company" (NASDAQ: NLNK) between September 17, 2013 and May 9, 2016 inclusive (the "Class Period".
NLNK: 9.81 (-0.50)
NewLink Genetics to Present Data on Indoximod at American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire - Fri Jun 03, 6:00AM CDT
NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will present two posters highlighting the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod, at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting on June 5 in Chicago.
NLNK: 9.81 (-0.50)
IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Investigation of NewLink Genetics Corporation and Advises Investors With Losses to Contact the Firm
BusinessWire - Thu Jun 02, 2:33PM CDT
Lundin Law PC announces it is investigating claims against NewLink Genetics Corporation ("NewLink" or the "Company" (Nasdaq: NLNK) concerning possible violations of federal securities laws. The investigation is related to allegations that certain statements issued by NewLink were false and misleading and/or failed to disclose material information regarding the Company's financial performance.
NLNK: 9.81 (-0.50)
NewLink Genetics to Participate in Jefferies Healthcare Conference
GlobeNewswire - Thu Jun 02, 6:00AM CDT
NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will participate in the Jefferies 2016 Healthcare Conference in New York.
NLNK: 9.81 (-0.50)
NewLink Genetics Corporation Top Infectious Disease Scientist to Present at Special Zika Conference Called by American Society for Microbiology
GlobeNewswire - Wed Jun 01, 6:00AM CDT
NewLink Genetics Corporation (NASDAQ:NLNK) today announced that Thomas P. Monath M.D., Chief Science Officer and Chief Operating Officer for the Infectious Disease Division of NewLink Genetics, will present at a scientific conference focused on the Zika virus hosted by the American Society for Microbiology (ASM) in collaboration with the American Society for Virology (ASV).
NLNK: 9.81 (-0.50)
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of NewLink Genetics Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 11, 2016 - NLNK
ACCESSWIRE - Tue May 31, 12:42PM CDT
NEW YORK, NY / ACCESSWIRE / May 31, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:
NLNK: 9.81 (-0.50)
NewLink Genetics to Participate in Baird Healthcare Conference
GlobeNewswire - Thu Sep 01, 6:00AM CDT
NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company focused on bringing novel immuno-oncology therapies to patients with cancer, today announced that it will participate in the Baird Healthcare Conference in New York.
NLNK: 9.81 (-0.50)
NewLink Genetics Reports Second Quarter 2016 Financial Results
GlobeNewswire - Fri Jul 29, 7:00AM CDT
- Management to Host Conference Call Today at 8:30 a.m. ET
NLNK: 9.81 (-0.50)
IMPORTANT SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against NewLink Genetics Corporation and Reminds Investors with Losses to Contact the Firm
BusinessWire - Thu Jun 23, 7:17PM CDT
Lundin Law PC announces a class action lawsuit has been filed against NewLink Genetics Corporation ("NewLink" or the "Company"
(Nasdaq: NLNK) concerning possible violations of federal securities laws between September 17, 2013 and May 9, 2016. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the July 11, 2016 lead plaintiff motion deadline. NLNK: 9.81 (-0.50)
The Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of NewLink Genetics Corporation Investors and Encourages Investors to Contact the Firm
BusinessWire - Thu Jun 23, 1:21PM CDT
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased NewLink Genetics Corporation ("NewLink" or the "Company"
(NASDAQ: NLNK) securities between September 17, 2013 and May 9, 2016, inclusive (the "Class Period". NewLink investors have until July 11, 2016 to file a lead plaintiff motion. NLNK: 9.81 (-0.50)
DEADLINE ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against NewLink Genetics Corporation and Reminds Investors with Losses to Contact the Firm
BusinessWire - Thu Jun 23, 4:30AM CDT
Lundin Law PC announces a class action lawsuit has been filed against NewLink Genetics Corporation ("NewLink" or the "Company"
(Nasdaq: NLNK) concerning possible violations of federal securities laws between September 17, 2013 and May 9, 2016. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the July 11, 2016 lead plaintiff motion deadline. NLNK: 9.81 (-0.50)
NEWLINK SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against NewLink Genetics Corporation - NLNK
PR Newswire - Fri Jun 10, 9:07PM CDT
Kahn Swick & Foti, LLC ("KSF"
and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 11, 2016 to file lead plaintiff applications in a securities class action lawsuit against NewLink Genetics Corporation (NasdaqGM: NLNK), if they purchased the Company's securities between September 17, 2013 and May 9, 2016, inclusive (the "Class Period". This action is pending in the United States District Court for the Southern District of New York. NLNK: 9.81 (-0.50)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in NewLink Genetics Corporation of Class Action Lawsuit and Upcoming Deadline - NLNK
ACCESSWIRE - Fri Jun 10, 5:21PM CDT
NEW YORK, NY / ACCESSWIRE / June 10, 2016 / Pomerantz LLP announces that a class action lawsuit has been filed against NewLink Genetics Corporation ("NewLink" or the "Company"
(NASDAQ: NLNK) and certain of its officers. The class action, filed in United States District Court, Southern District of New York, and docketed under 16-cv-03545, is on behalf of a class consisting of all persons or entities who purchased NewLink securities between September 17, 2013 and May 9, 2016 inclusive (the "Class Period". This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act". NLNK: 9.81 (-0.50)
INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Class Action Involving NewLink Genetics Corporation and a Lead Plaintiff Deadline of July 11, 2016 - NLNK
GlobeNewswire - Fri Jun 10, 9:51AM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased NewLink Genetics Corporation (NASDAQ:NLNK) securities between September 17, 2013 and May 9, 2016.
NLNK: 9.81 (-0.50)
How These Biotech's Stocks are Performing? - Clovis Oncology, Illumina, NewLink Genetics and Zafgen
PR Newswire - Thu Jun 09, 7:00AM CDT
Some of the biggest opportunities in the equities market are found in tumultuous industries such as Biotechnology. The segment continues to present a number of remarkable trades as well as potentially good investment that are waiting to be discovered. This morning ActiveWallSt.com features these four biotech stocks in its technical alerts service: Clovis Oncology Inc. (NASDAQ: CLVS), Illumina Inc. (NASDAQ: ILMN), NewLink Genetics Corp. (NASDAQ: NLNK), and Zafgen Inc. (NASDAQ: ZFGN). Learn more about these stocks and receive your complimentary trade alerts at:
ZFGN: 2.94 (-0.10), CLVS: 23.38 (-0.21), NLNK: 9.81 (-0.50), ILMN: 167.90 (-0.66)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in NewLink Genetics Corporation to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit - NLNK
GlobeNewswire - Wed Jun 08, 2:22PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of NewLink Genetics Corporation (Nasdaq:NLNK) ("NewLink" or the "Company"
securities during the period between September 17, 2013 and May 9, 2016, inclusive (the "Class Period". Investors with losses in excess of $100,000 who wish to become proactively involved in the litigation have until July 11, 2016 to seek appointment as lead plaintiff. NLNK: 9.81 (-0.50)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of NewLink Genetics Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 11, 2016 - NLNK
GlobeNewswire - Mon Jun 06, 2:18PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
NLNK: 9.81 (-0.50)
Law Offices of Marc S. Henzel Announces Investigation of Companies for Violations of the Federal Securities Laws
PR Newswire - Mon Jun 06, 8:11AM CDT
The Law Offices of Marc S. Henzel (www.henzellaw.com), a firm focusing on shareholder litigation, gives notice to shareholders of investigation into the following securities for violations of the Federal Securities Laws:
TNGO: 9.65 (+0.13), ENDP: 19.92 (-0.31), GGB: 2.88 (+0.18), HCP: 39.06 (+0.26), UNIS: 2.79 (+0.01), NLNK: 9.81 (-0.50), ABIL: 4.52 (+0.03)
NewLink Genetics Presents Clinical Data for IDO Pathway Inhibitor Indoximod Combinations at American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire - Mon Jun 06, 6:00AM CDT
NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company focused on bringing novel immuno-oncology medicines to patients, yesterday presented data from two studies on two posters highlighting the combination therapeutic potential of indoximod, an indoleamine-(2,3)-dioxygenase (IDO) pathway inhibitor, at the 2016 American Society of Clinical Oncology Annual Meeting in Chicago.
NLNK: 9.81 (-0.50)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against NewLink Genetics Corporation (NLNK) and Lead Plaintiff Deadline: July 11, 2016
ACCESSWIRE - Fri Jun 03, 9:51AM CDT
NEW YORK, NY / ACCESSWIRE / June 3, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed on behalf of those who purchased shares of NewLink Genetics Corporation ("NewLink" or the "Company"
(NASDAQ: NLNK) between September 17, 2013 and May 9, 2016 inclusive (the "Class Period". NLNK: 9.81 (-0.50)
NewLink Genetics to Present Data on Indoximod at American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire - Fri Jun 03, 6:00AM CDT
NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will present two posters highlighting the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod, at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting on June 5 in Chicago.
NLNK: 9.81 (-0.50)
IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Investigation of NewLink Genetics Corporation and Advises Investors With Losses to Contact the Firm
BusinessWire - Thu Jun 02, 2:33PM CDT
Lundin Law PC announces it is investigating claims against NewLink Genetics Corporation ("NewLink" or the "Company"
(Nasdaq: NLNK) concerning possible violations of federal securities laws. The investigation is related to allegations that certain statements issued by NewLink were false and misleading and/or failed to disclose material information regarding the Company's financial performance. NLNK: 9.81 (-0.50)
NewLink Genetics to Participate in Jefferies Healthcare Conference
GlobeNewswire - Thu Jun 02, 6:00AM CDT
NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will participate in the Jefferies 2016 Healthcare Conference in New York.
NLNK: 9.81 (-0.50)
NewLink Genetics Corporation Top Infectious Disease Scientist to Present at Special Zika Conference Called by American Society for Microbiology
GlobeNewswire - Wed Jun 01, 6:00AM CDT
NewLink Genetics Corporation (NASDAQ:NLNK) today announced that Thomas P. Monath M.D., Chief Science Officer and Chief Operating Officer for the Infectious Disease Division of NewLink Genetics, will present at a scientific conference focused on the Zika virus hosted by the American Society for Microbiology (ASM) in collaboration with the American Society for Virology (ASV).
NLNK: 9.81 (-0.50)
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of NewLink Genetics Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 11, 2016 - NLNK
ACCESSWIRE - Tue May 31, 12:42PM CDT
NEW YORK, NY / ACCESSWIRE / May 31, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:
NLNK: 9.81 (-0.50)
